Przezskórne interwencje wieńcowe u pacjentów chorych na cukrzycę typu 2. Stenty uwalniające leki antyproliferacyjne a problem restenozy

Czasopismo : Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna
Tytuł artykułu : Przezskórne interwencje wieńcowe u pacjentów chorych na cukrzycę typu 2. Stenty uwalniające leki antyproliferacyjne a problem restenozy

Autorzy :
Paprocka-Borowicz, M.
Katedra Fizjoterapii, Akademia Medyczna, ul. Grunwaldzka 2, 50-355 Wrocław, tel. +48 (0) 71 784 01 83, małgorzata.paprocka@am.wroc.pl,
Ciejka, E.
Wyższa Szkoła Kosmetologii i Ochrony Zdrowia w Białymstoku, ul. Krakowska 9, 15-875 Białystok; Wojewódzki Ośrodek Medycyny Pracy Centrum Profilaktyczno-Lecznicze, Zakład Rehabilitacji Leczniczej,ul. Aleksandrowska 61/63, 91-205 Łódź, +48 (0) 42 272 18, e.ciejka@wompcpl.eu,
Zalewski, P.
Katedra i Zakład Higieny i Epidemiologii Collegium Medicum im. Ludwika Rydygiera, Uniwersytet Mikołaja Kopernika w Toruniu, ul. M. Skłodowskiej-Curie 9, 85-094 Bydgoszcz,
Szyguła, R.
Katedra Aktywnych Form Turystyki i Rekreacji, Wydział Wychowania Fizycznego i Fizjoterapii, Politechnika Opolska, ul. Prószkowska 76 45-758 Opole, tel. +48 (0) 77 400 04 50, r.szygula@po.opole.pl,
Kielnar, R.
Instytut Fizjoterapii, Wydział Medyczny, Uniwersytet Rzeszowski, ul. Warszawska 26a,35-205 Rzeszów, tel. +48 (0) 17 872 19 20, kielnarrenata@o2.pl,
Boerner, E.
Katedra Fizjoterapii, Akademia Wychowania Fizycznego, ul. Paderewskiego 35, 51-617 Wrocław, tel. +48 (0) 71 347 30 90, ewa.boerner@awf.wroc.pl,
Socha, A.
Zakład Propedeutyki i Fizykodiagnostyki Stomatologicznej, Pomorska Akademia Medyczna, al. Powstańców Wlkp. 72, 70-111 Szczecin, tel. +48 (0) 91 466 16 73, zpropst@sci.pam.szczecin.pl,
Witoś, M.
Akademia Wychowania Fizycznego, Wydział Fizjoterapii, Katedra Fizjoterapii, ul Paderewskiego 32, 51-617 Wrocław, tel. +48 (0) 71 347 30 75, halina.podbielska@awf.wroc.pl,
Broniec, A.
Wydział Fizyki i Informatyki Stosowanej/Laboratorium Biocybernetyki EAiIE, Akademia Górniczo-Hutnicza, al. Mickiewicza 30, 30-059 Kraków, tel. +48 (012) 617-38-73, broniec@novell.ftj.agh.edu.pl,
Wieczorski, M.
Szpitalny Oddział Ratunkowy Samodzielnego Publicznego Szpitala Klinicznego nr 4 w Lublinie ul. Jaczewskiego 8, 20-954 Lublin, mwieczorski@spsk4.lublin.pl,
Winiarska, H.
Prywatna Klinika Kardiologii NSZOZ w Tychach,
Bachórzewska-Gajewska, H.
Klinika Kardiologii Inwazyjnej, Uniwersytet Medyczny w Białymstoku, ul. M. Curie-Skłodowskiej 24a, 15-276 Białystok, tel. +48 (0) 85 74 68 496, hgajewska@op.pl,
Abstrakty : Na świecie notuje się coraz więcej zachorowań na cukrzycę, której częstym następstwem jest choroba wieńcowo-naczyniowa. Wyniki przezskórnej interwencji wieńcowej (PCI), a także operacji pomostowania aortalno-wieńcowego (CABG) u pacjentów chorych na cukrzycę typu 2 są w tym przypadku mniej korzystne. Implementacja stentów wieńcowych uwalniających leki pozwoliła poprawić efekty kliniczne, głównie dzięki zminimalizowaniu stopnia restenozy. Celem pracy jest podsumowanie aktualnego stanu wiedzy, dotyczącego efektywności oraz bezpieczeństwa stosowania stentów uwalniających leki antyproliferacyjne u pacjentów chorych na cukrzycę typu 2.

Cardiovascular disease is a major consequence of this chronic condition. Outcomes after percutaneous coronary interventions (PCI) and coronary artery bypass grafting (CABG) are worse in patients with diabetes mellitus (DM) compared with those without DM. Drugs eluting stents implantation has improved the clinical outcomes of diabetic patients, especially the reduction of restenosis rate. The purpose of this review is to summarize the current achievements relating to the effectiveness and safety of drug eluting stents in diabetic patients.

Słowa kluczowe : stenty uwalniające leki, restenoza, cukrzyca, drug eluting stents, restenosis, diabetes mellitus,
Wydawnictwo : Indygo Zahir Media
Rocznik : 2009
Numer : Vol. 15, nr 3
Strony : 265 – 272
Bibliografia : 1. C. Berry, J.C. Tardif, M.G. Bourassa: Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management, J Am Coll. Cardiol., vol. 49(6), 2007, s. 631-642.
2. C. Berry, J.C. Tardif, M.G. Bourassa: Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization, J. Am. Coll. Cardiol., vol. 49(6), 2007, s. 643-656.
3. M.J. Magee, T.M. Dewey, T. Acuff i in.: Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass, Ann. Thorac. Surg., vol. 72, 2001, s. 776-780; dyskusja: 780-781.
4. N.W. Niles, P.D. McGrath, D. Malenka i in.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study: Northern New England Cardiovascular Disease Study Group, J. Am. Coll. Cardiol., vol. 37, 2001, s. 1008-1015.
5. D. Hasdai, C.B. Granger, S.S. Srivatsa i in.: Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes, J. Am. Coll. Cardiol., vol. 35, 2000, s. 1502-1512.
6. K.P. Morgan, A. Kapur, K.J. Beatt i in.: Anatomy of coronary disease in dia-betic patients: an explanation for poorer outcomes after percutaneous coronary inter-vention and potential target for intervention, Heart, vol. 7, 2004, s. 732-738.
7. A. Cieśliński, A. Pająk, P. Podolec, A. Rynkiewicz: POLSCREEN – Ogólnopolski Program Prewencji Choroby Wieńcowej.
8. Przezskórne interwencje wieńcowe. Wytyczne postępowania Europejskiego Towarzystwa Kardiologicznego (European Society of Cardiology-ESC), Kardiol. Pol., vol. 63, 2005, (supl. 3), s. 5.
9. D.L. Fischman, M.B. Leon, D.S. Baim i in.: A randomized comparison of coronary-stent placement and balloon-angioplasty in the treatment of coronary artery disease, N. Engl. J. Med., vol. 331, 1994, s. 496-501.
10. A. Betriu, M. Masotti, A. Serra i in.: Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up, J. Am. Coll. Cardiol., vol. 5, 1999, s. 1498-1506.
11. C. Macaya, P.W. Serruys, P. Ruygrok i in.: Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group, J. Am. Coll. Cardiol., vol. 2, 1996, s. 255-261.
12. F. Kiemeneij, P.W. Serruys, C. Macaya i in.: Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial, J. Am. Coll. Cardiol., vol. 6, 2001, s. 1598-1603.
13. S.R. Wilson, B.A. Vakili, W. Sherman i in.: Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4,284 cases, Diabet. Care, vol. 5, 2004, s. 1137-1142.
14. M.P. Savage, D.L. Fischman, R.A. Schatz i in.: Coronary intervention in the diabetic patient: improved outcome following stent implantation compared with balloon angioplasty, Clin. Cardiol., vol. 25, 2002, s. 213-217.
15. A. Abizaid, R. Kornowski, G.S. Mintz i in.: The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation, J. Am. Coll. Cardiol., vol. 32, 1998, s. 584-589.
16. S. Elezi, A. Kastrati, J. Pache i in.: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement, J. Am. Coll. Cardiol., vol. 32, 1998, s. 1866-1873.
17. T. Joseph, J. Fajadet, C. Jordan i in.: Coronary stenting in diabetics: immediate and mid-term clinical outcome, Catheter Cardiovasc. Interv., vol. 47, 1999, s. 279-284.
18. P.W. Serruys, P. de Jaegere, F. Kiemeneij i in.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease, N. Engl. J. Med., vol. 331, 1994, s. 489-495.
19. V. Mathew, B.J. Gerh, B.A. Wiliams i in.: Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, Circulation, vol. 4, 2004, s. 476-480.
20. J.E. Sousa, M.A. Costa, A. Abizaid i in.: Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents, Circulation, vol. 18, 2005, s. 2326-2329.
21. B.J. Rensing, J. Vos, P.C. Smits i in.: Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up, Eur. Heart J., vol. 22, 2001, s. 2125-2130.
22. M.C. Morice, P.W. Serruys, J.E. Sousa i in.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N. Eng. J. Med., vol. 23, 2002, s. 1773-1780.
23. I. Moussa, M.B. Leon, D.S. Baim i in.: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy, Circulation, vol. 19, 2004, s. 2273-2278.
24. J. Schofer, M. Schluter, A.H. Gershlick i in.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS), Lancet, vol. 362, 2003, s. 1093-1099.
25. E. Schampaert, E.A. Cohen, M. Schluter i in.: The Canadian study of sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS), J. Am. Coll. Cardiol., vol. 43, 2004, s. 1110-1115.
26. E. Grube, S. Silber, K.E. Hauptmann i in.: TAXUS I: six and twelve-months results from a randomised, double-blind trial on a slow -release paclitaxel-eluting stent for de novo coronary lesions, Circulation, vol. 107, 2003, s. 38-42.
27. A. Colombo, J. Drzewiecki, A. Banning i in.: Randomized study to assess the effectiveness of slow- and moderate release polymer-based paclitaxel-eluting sents for coronary artery lesions, Circulation, vol. 108, 2003, s. 788-794.
28. G.W. Stone, S.G. Ellis, D.A. Cox i in.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease, N. Engl. J. Med., vol. 350, 2004, s. 221-231.
29. V. Aloke, I.F. Palacios, A. Kastrati i in.: Drug-eluting stents for diabetes mellitus. A rush to judment?, J. Am. Coll. Cardiol., vol. 45, 2005, 479-483.
30. M. Sabate, P. Jimenez-Quevedo, D.J. Angiolillo i in.: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial, Circulation, vol. 112, 2005, s. 2175-2183.
31. R.A. Corpus, P.B. George, J.A. House i in.: Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention, J. Am. Coll. Cardiol., vol. 1, 2004, s. 8-14.
32. R. Kornowski, S. Fuchs: Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions, J. Am. Coll. Cardiol., vol. 1, 2004, s. 15-17.
33. M.C. Morice, A. Colombo, B. Meier i in.: Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial, JAMA, vol. 8, 2006, s. 895-904.
34. S. Windecker, A. Remondino, F.R. Eberli i in.: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization, N. Engl. J. Med., vol. 353, 2005, s. 653-662.
35. A. Dibra, A. Kastrati, J. Mehilli i in.: Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients, N. Engl. J. Med.,vol. 7, 2005, s. 663-670.
36. Y.H. Kim, S.W. Park, S.W. Lee i in.: Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease, Circulation, vol. 20, 2006, s. 2148-2153.
37. A. Kastrati, J. Mehilli, N. von Beckerath i in.: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial, JAMA, vol. 293, 2005, s. 165-171.
38. S.W. Lee, S.W. Park, Y.H. Kim i in.: A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus, J Am. Coll. Cardiol., vol. 52, 2008, s. 727-733.
39. C. Stettler, S. Jenni, S. Allemann i in.: Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of randomized controlled trials, Heart, vol. 92, 2006, s. 650-657.
40. A.T. Ong, J. Aoki, C.A. van Mieghem i in.: Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from RESEARCH and T-SEARCH registries), Am. J. Cardiol, vol. 96, 2005, s. 358-362.
41. P. Urban, A.H. Gershlick, G. Guagliumi i in.: Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry, Circulation, vol. 113, 2006, s. 1434-1441.
42. P.. Garg, S.T. Normand, T.S. Silbaugh, i in.: Drug-eluting oraz bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry, Cirulation., vol. 118, 2008, s. 2277-2285.
43. S.M. Haffner, A.S. Greenberg, W.M. Weston i in.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, Circulation, vol. 106, 2002, s. 679-684.
44. S.M. Haffner: Insulin resistance, inflammation, and the prediabetic state, Am. J. Cardiol., vol. 92, 2003, s. 18J-26J.
45. R.E. Law, W.P. Meehan, X.P. Xi i in.: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia, J. Clin. Invest., vol. 98, 1996, s. 1897-1905.
46. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease, N. Eng. J. Med., vol. 335, 1996, s. 217-225.
47. BARI Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status, J. Am. Coll. Cardiol., vol. 35, 2000, s. 1122-1129.
48. The BARI Investigators: The final 10-year follow-up results from BARI randomized trial, J.Am. Coll. Cardiol., vol. 49, 2007, s. 1600-1606.
49. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart. J., vol. 28, 2007, s. 88-136.
50. P.W. Serruys, A.T. Ong, L.A. van Herwerden i in.: Five year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial revascularization Therapies STUDY (ARTS) randomized trial, A. Am. Coll. Cardiol., vol. 46, 2005, s. 575-581.
51. A.E. Rodriguez, J. Baldi, C. Fernandez Pereira i in.: Five-year follow-up of the Argentine Randomized Trial of Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients With Multiple Vessel Disease (ERACI II), J. Am. Coll. Cardiol., vol. 46, 2005, s. 582-588.
52. W. Hueb, N.H. Lopes, B.J. Gersh i in.: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease, Cirulation, vol. 115, 2007, s. 1082-1089.
53. D.M. Bravata, A.L. Gienger, K.M. McDonald i in.: Systematic review: The Comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery, Ann. Intern. Med., vol. 147, 2007, s. 703-716.
54. A.P. Kappetein, K.D. Dawkins, F.W. Mohr i in.: Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease: insights from SYNTAX run-in phase, Eur. J. Cardiothorac, vol. 29, 2006, s. 486-491.
55. P.W. Serruys, M.C. Morice, A.P. Kappetein i in.: Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease, N. Engl. J. Med., vol. 360, 2009, s. 961-972.
56. BARDI 2D Study Group, R.L. Frye, P. August, M.M. Brooksi in.: A randomized trial of therapies for type 2 diabetes and coronary artery disease, N. Eng. J. Med., vol. 360, 2009, s. 2503-2015.
57. E. Camenzind: Safety of drug eluting stents: a meta-analysis of first genaration DES programs; A. Nordmann: Safety of drug-eluting stents: insights from a meta-analysis. Hot Lines and Clinical Trial Updates, World Congress of Cardiology, Barcelona, 2006.
58. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser i in.: Late clinical events after clopidogrel discontinuation may limit benefit of drug-eluting stents: an observation study of drug-eluting versus bare-metal stents, J. Am. Coll. Cardiol., vol. 48, 2006, s. 2584-2591.
59. A.T. Ong, A. Hoye, J. Aoki i in.: Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus or paclitaxel stent implantation, J. Am. Coll. Cardiol., vol. 45, 2005, s. 947-953.
60. I. Iakovou, T. Schmidt, E. Bonizzoni i in.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents, JAMA, vol. 293, 2005, s. 216-230.
61. K.F. Dou, B. Xu, Y.J. Yang i in.: Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients; results from a real-word single center registry, Chin. Med. J., vol. 122, 2009, s. 612-616.
62. M. Joner, A.V. Finn, A. Farb i in.: Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk, J. Am. Coll. Cardiol., vol. 48, 2006, s. 193-202.
63. D.W. Park, S.W. Park, K.H. Park i in.: Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up, J. Am. Coll. Cardio., vol. 98, 2006, s. 352-356.
64. S.B. King III, S.C. Smith Jr., J.W. Hirshfeld i in.: 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines, J. Am. Coll. Cardiol., vol. 51, 2008, s. 172-209.
DOI :
Cytuj : Paprocka-Borowicz, M. ,Ciejka, E. ,Zalewski, P. ,Szyguła, R. ,Kielnar, R. ,Boerner, E. ,Socha, A. ,Witoś, M. ,Broniec, A. ,Wieczorski, M. ,Winiarska, H. ,Bachórzewska-Gajewska, H. , Przezskórne interwencje wieńcowe u pacjentów chorych na cukrzycę typu 2. Stenty uwalniające leki antyproliferacyjne a problem restenozy. Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna Vol. 15, nr 3/2009
facebook